Clinical Trial Detail

NCT ID NCT02959437
Title Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Incyte Corporation
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

colorectal cancer

Therapies

Azacitidine + Epacadostat + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.